As of November 4, 2026, Artiva Biotherapeutics, Inc. is a publicly traded company (Nasdaq: ARTV). The largest holder reporting an active stake on Schedule 13D is RA Capital, at 37.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Viking Global (5.4%) (Schedule 13D/A, July 23, 2026).
Is this your company?
About to sign with, pay or invest in Artiva Biotherapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Artiva Biotherapeutics, Inc. a real, registered company?
- Artiva Biotherapeutics, Inc. files with the SEC under CIK 1817241 (its SEC filings).
- Its shares are listed under the ticker ARTV on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ARTIVA BIOTHERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-04).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-10-27) and 1 state WARN notice (latest 2026-10-27, San Diego CA, 131 employees).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RA Capital (filed 2026-07-23).
Who are Artiva Biotherapeutics, Inc.'s owners and officers?
Artiva Biotherapeutics, Inc.: incorporated in Delaware; business address in San Diego, California; industry Biological Products, (No Diagnostic Substances) (Form 8-K, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Venrock Healthcare Capital Partners Iii, L.P. | 4.2% |
| Schedule 13G/A, 2026-08-10 | Andrew J. Schwab | 4.8% |
| Schedule 13D/A, 2026-07-23 | Ra Capital Management, L.P. | 37.9% |
| Schedule 13D/A, 2026-06-15 | Ra Capital Management, L.P. | 36.6% |
| Schedule 13D/A, 2026-05-28 | Gc Corp | 12.3% |
| Schedule 13G, 2026-05-18 | Viking Global Investors LP | 5.4% |
| Schedule 13D/A, 2026-05-13 | Ra Capital Management, L.P. | 33.7% |
| Schedule 13G/A, 2025-07-16 | Blackrock, Inc. | 2% |
Questions about who owns Artiva Biotherapeutics, Inc.
Who owns Artiva Biotherapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Artiva Biotherapeutics, Inc.: Ra Capital Management, L.P. (37.9%, Schedule 13D/A, filed 2026-07-23), Gc Corp (12.3%, Schedule 13D/A, filed 2026-05-28) and Viking Global Investors LP (5.4%, Schedule 13G, filed 2026-05-18).
Who are the largest shareholders of Artiva Biotherapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Artiva Biotherapeutics, Inc. on this page are Ra Capital Management, L.P. (37.9%), Gc Corp (12.3%) and Viking Global Investors LP (5.4%).
When did Ra Capital Management, L.P. buy into Artiva Biotherapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13D/A, filed 2026-05-13, reporting 33.7%; its latest, Schedule 13D/A filed 2026-07-23, reports 37.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Artiva Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Artiva Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Artiva Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Artiva Biotherapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- RA Capital Nexus Fund III, L.P., a director: 17,329,570 shares (35.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-07-31).
- , a director and 10% owner: 17,329,570 shares (35.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-07-31).
- , a director and 10% owner: 17,329,570 shares (35.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-07-31).
- RA Capital, a director and 10% owner: 17,329,570 shares (35.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-07-31).
- RA Capital Nexus Fund, L.P., a director: 17,329,570 shares (35.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-07-31).
Shares outstanding: 48,890,121 as of 2026-07-31, from the company's latest SEC cover page.
How much has Artiva Biotherapeutics, Inc. raised?
Latest IPO step: Artiva Biotherapeutics, Inc. filed its final IPO prospectus (424B4, 2024-07-22).
IPO filings: 424B4, 2024-07-22, S-1/A, 2024-07-15.
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-10-27).
Keep reading
More on Artiva Biotherapeutics, Inc. and the records around it.
Artiva Biotherapeutics, Inc. elsewhere on the record
- Layoff notices Oct 2026
- 5%+ stake filings Aug 2026
Companies that share a holder
- 5AM Ventures VI, L.P. also filed stake reports on 2 other companies: CAMP4 THERAPEUTICS CORPORATION (Aug 2026), VOR BIOPHARMA INC. (Jul 2025)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/artiva-biotherapeutics